<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317148</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-205</org_study_id>
    <nct_id>NCT00317148</nct_id>
  </id_info>
  <brief_title>Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women</brief_title>
  <official_title>Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4
      months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in
      postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Humans, along with the other primates, are unique among animal species in having adrenals
      that secrete large amounts of the inactive precursor steroids dehydroepiandrosterone (DHEA)
      and especially its sulfate DHEA-S. The marked reduction in the formation of DHEA-S by the
      adrenals during aging results in a dramatic fall in the formation of androgens and estrogens
      in peripheral target tissues, a situation that has been proposed to be associated with
      age-related diseases including skin atrophy, insulin resistance and obesity. Much attention
      has been given to the benefits of DHEA administered to postmenopausal women, especially on
      the bone, skin, vagina and well being after oral as well as percutaneous administration of
      the precursor steroid.

      This study proposes to study the effect of 50 mg oral DHEA capsules during a period of 4
      months administered to postmenopausal women experiencing 50 or more moderate to severe hot
      flushes per week. Participants will be stratified by the number of hot flushes experienced
      per week. The two strata are: 50-70 or more than 70 hot flushes per week. During the study
      several biological and clinical parameters will be evaluated, as well as the reduction of the
      number of hot flashes and improvement of overall quality of life.

      Subjects will be evaluated at specific time intervals during the study for the above
      mentioned parameters as well as tolerability and adverse reactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use of a diary to monitor the number and intensity of hot flashes as compared to placebo at screening, day 1, weeks 2, 4, 8, 12 and 16</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety as well as quality of life, psychological general well being, and sexual life by questionnaires at day 1, 2, 4, 8, 12 and 16 weeks of treatment</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA capsule</intervention_name>
    <description>One capsule of DHEA</description>
    <arm_group_label>DHEA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women with 50 or more moderate to severe hot flushes.

          -  Women between 40 to 70 years of age.

        Exclusion Criteria:

          -  Body mass index (BMI) of 35 kg/m2 or more.

          -  Significant metabolic and endocrine diseases.

          -  Diagnosis of cancer.

          -  Use of steroids or drugs that interfere with the metabolism of estrogen.

          -  Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to
             randomization.

          -  Use of alternative therapies or natural products to treat postmenopausal symptoms in
             the four weeks prior to randomization.

          -  Palpable fibroids or uterine prolapse: Grade 2 or 3.

          -  Cigarette smoking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonello Cusan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUL Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernand Labrie, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHUL Research Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique des Traitements Hormonaux</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab. 2001 Oct;86(10):4686-92.</citation>
    <PMID>11600526</PMID>
  </reference>
  <reference>
    <citation>Baulieu EE. Neuroactive neurosteroids: dehydroepiandrosterone (DHEA) and DHEA sulphate. Acta Paediatr Suppl. 1999 Dec;88(433):78-80.</citation>
    <PMID>10626550</PMID>
  </reference>
  <reference>
    <citation>Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994 Oct;79(4):1086-90.</citation>
    <PMID>7962278</PMID>
  </reference>
  <reference>
    <citation>Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996 Sep;150 Suppl:S43-50.</citation>
    <PMID>8943786</PMID>
  </reference>
  <reference>
    <citation>Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab. 1999 May;84(5):1527-33.</citation>
    <PMID>10323374</PMID>
  </reference>
  <reference>
    <citation>Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male. 2003 Sep;6(3):151-6.</citation>
    <PMID>14628495</PMID>
  </reference>
  <reference>
    <citation>Labrie F. Intracrinology. Mol Cell Endocrinol. 1991 Jul;78(3):C113-8. Review.</citation>
    <PMID>1838082</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997 Aug;82(8):2396-402.</citation>
    <PMID>9253307</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997 Oct;82(10):3498-505.</citation>
    <PMID>9329392</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Simard J, Luu-The V, Belanger A, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rheaume E, Labrie C, Lachance Y. The 3B-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3B-HSD congenital deficiency.In: Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. Hansson, V., Levy, F.O. and Tasken, K. (eds.), Berlin, Heidelberg, New York, Springer-Verlag, Vol. Suppl. 2:pp. 185-218, 1996.</citation>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2006</study_first_submitted>
  <study_first_submitted_qc>April 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2006</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot Flashes</keyword>
  <keyword>Menopause</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Hot flushes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

